Bio-Thera Solutions Ltd (SHA: 688177), a Chinese biopharmaceutical company, has announced that it has received approval from the National Medical Products Administration (NMPA) to conduct a combined Phase Ib/II clinical study for its pipeline drugs BAT7104 and BAT4706 in patients with advanced malignant tumors.
BAT7104 is a bispecific antibody (BsAb) that targets both PD-L1 and CD47, designed to activate macrophages to engulf tumor cells by blocking the CD47/SIRPα pathway. Additionally, it enhances anti-tumor effects by combining T cells with macrophages through the inhibition of the PD-L1/PD-1 pathway.
BAT4706 is a monoclonal antibody (mAb) that targets the cytotoxic T-lymphocyte antigen 4 (CTLA-4), developed for the treatment of advanced solid tumors. This molecule specifically binds to CTLA-4, an immune checkpoint found on regulatory T cells and activated CD4+ and CD8+ T cells, thereby restoring T cell activation, enhancing antibody-dependent cytotoxicity, and bolstering the body’s anti-tumor immune response.- Flcube.com
